The exercise period for Prostatype Genomics AB’s warrants of series TO 2 commences today
Prostatype Genomics AB ("Prostatype Genomics" or “the Company") announces that the exercise period for warrants of series TO 2 ("TO 2") begins today, March 9, 2023. The exercise period runs through March 30, 2023. Holders of TO 2 have the right to subscribe for one (1) new share in Prostatype Genomics at a price of SEK 2.90 per share for each warrant. Through full exercise of TO 2, the Company can receive a maximum of approximately SEK 22.5 million before issue costs. An information sheet is available on the respective websites of Prostatype Genomics (www.prostatypegenomics.com), Sedermera